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Alterations in RNA splicing are frequent in human
tumors. Two recent studies of lymphoma and breast
cancer have identified components of the
spliceosome — the core splicing machinery — that
are essential for malignant transformation driven by
the transcription factor MYC. These findings provide
a direct link between MYC and RNA splicing
deregulation, and raise the exciting possibility of
targeting spliceosome components in MYC-driven
tumors.HNRNPH, have oncogenic properties, whereas others,
including RBM5, RBM6 or RBM10, act as tumor sup-Spliceosome alterations in cancer
We have known for many years that human tumors ex-
hibit abnormal splicing patterns. But in the past few years,
we have started to appreciate that many of these changes
reflect alterations in particular components of the splicing
machinery. The core spliceosome (and associated regula-
tory factors) comprises more than 300 proteins and five
small nuclear RNAs (snRNAs), and catalyzes both consti-
tutive and regulated alternative splicing [1]. The U1, U2,
U4, U5, and U6 snRNAs participate in several key RNA–
RNA and RNA–protein interactions during spliceosome
assembly and splicing catalysis. These snRNAs associate
with seven ‘Sm’ core proteins and additional proteins to
form small nuclear ribonucleoprotein (snRNP) particles.
Other protein subcomplexes, such as the SF3A and SF3B
complexes as well as the PRP19-associated complexes
dubbed NTC and NTR, also play key roles in RNA
splicing. The architecture of the spliceosome undergoes
extensive remodeling in preparation for, during, and after
splicing.
Recently, large-scale sequencing projects have identi-
fied recurrent somatic mutations in certain components
of the spliceosome, such as SF3B1, U2AF1, SRSF2 and* Correspondence: krainer@cshl.edu
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including myelodysplastic syndromes (MDS), other mye-
loid neoplasms, and chronic lymphocytic leukemia
(reviewed in [2]). The mutations that affect SRSF2 or
U2AF1 directly impair hematopoietic differentiation
in vivo, and result in changes in mRNA splicing pat-
terns. Interestingly, in the case of SRSF2, the mutant
protein exhibits altered RNA-binding specificity, rather
than a loss of RNA-binding activity [2].
In addition, changes in splicing factor levels are fre-
quently present in solid tumors. Several regulatory spli-
cing factors, such as SRSF1, SRSF6, HNRNPA2/B1 or
pressors (reviewed in [3]). These RNA-binding proteins
elicit changes in alternative splicing in a concentration-
dependent manner, and, thus, changes in their levels can
alter the pre-mRNA splicing of many genes related to
cancer, even in the absence of mutations. Alternative
splicing has been linked to cancer through post-
transcriptional regulation of components of many of the
cellular processes considered to be ‘hallmarks’ of cancer,
including cell proliferation, apoptosis, metabolism, inva-
sion, and angiogenesis, but the biological consequences
of these global changes in alternative splicing are only
beginning to be unraveled.
Two recent studies [4, 5] have revealed that components
of the spliceosome are essential for MYC (a transcription
factor) to function as an oncoprotein. AsMYC is the most
frequently amplified oncogene in human cancers and
plays a crucial role in transformation, therapies that ex-
ploit the spliceosome would be very attractive.MYC and alternative splicing in cancer
Previous work linked MYC and alternative splicing by
demonstrating that genes that encode certain splicing
activators and repressors, such as SRSF1, HNRNPA1,
HNRNPA2 or PTB, are direct transcriptional targets of
MYC [3, 6, 7]. Furthermore, SRSF1 has been shown not
only to contribute to MYC’s oncogenic activity [7] butThis article is distributed under the terms of the Creative Commons Attribution
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promoting the formation of more-aggressive breast tu-
mors [6]. The recent reports by Koh et al. [5] and Hsu
et al. [4] have provided a direct link between MYC and
the core splicing machinery by identifying components ofSpliceosome core
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two of the proteins frequently mutated in MDS; SNRPF,
one of the Sm proteins of spliceosomal snRNPs; EFTUD2,
a component of U5 snRNP; and BUD31, a protein associ-
ated with the PRP19-related or NTR complex [1]. Not-
ably, BUD31 knockdown in the MYC hyperactivated state
led to decreased cell viability and increased apoptosis, and
was associated with the accumulation of transcripts with
one or more retained introns. The authors observed a de-
crease in poly(A) + RNA after actinomycin D treatment,
which they interpreted as symptomatic of a defect in pre-
mRNA maturation and/or stability. Interestingly, BUD31
knockdown did not confer sensitivity to cells expressing
human epidermal growth factor receptor 2 (HER2) or epi-
dermal growth factor receptor (EGFR), demonstrating that
limiting BUD31 is not synthetic lethal with all oncogenes.
Finally, pharmacological inhibition of the core spliceo-
some component SF3B1 reduced the tumorigenic and
metastatic potential of MYC-driven human breast cancer
cell lines. The authors suggest that oncogenic MYC over-
loads the splicing machinery in mammary epithelial cells
by increasing total transcript levels, making the cells more
sensitive to perturbations in splicing fidelity.
In parallel work, Koh and colleagues identified several
components of the splicing machinery as key effectors of
MYC in lymphomagenesis in the Eμ-myc mouse model
[5]. In this model, transgenic mice express the c-myc
oncogene under the control of the IgM heavy-chain en-
hancer, and reproducibly develop and die from tumors of
the B-lymphocyte lineage. These authors report that
during lymphomagenesis, MYC directly upregulates tran-
scription of genes encoding snRNP constituents or snRNP
assembly factors, including: GEMIN5, a component of the
SMN complex that loads a ring of seven Sm proteins onto
snRNAs; the Sm proteins SNRPD1, SNRNPD3, and
SNRNPB; the arginine methyltrantransferase PRMT5,
which methylates arginines in the Sm proteins; and
WDR77, a non-catalytic component of the ormethylo-
some, a methyltransferase complex. In addition, lymph-
oma development was delayed in Eμ-myc-PRMT5+/−
mice. PRMT5 depletion led to a reduction of Sm protein
methylation, which was associated with the accumulation
of retained introns and the skipping of alternative exons
that have weak 5′ splice sites, and it resulted in increased
apoptosis. Furthermore, by using antisense oligonucleo-
tides, the authors demonstrate the contribution of several
splicing events to the PRMT5+/− phenotype in Eμ-myc B
cells. These findings suggest that in B lymphocytes, onco-
genic MYC reprograms the spliceosome to drive inclusion
of alternative exons with weak 5′ splice sites.
Both studies uncovered an essential role of the splicing
machinery in MYC-driven transformation, and identify
multiple associated abnormal splicing events, including in-
tron retention. Interestingly, widespread intron retentionwas recently described as a common event across human
tumors, even in the absence of mutations that directly
affect the spliceosome [8]. In addition, changes in intron
processing have been reported during embryonic develop-
ment, as well as during the response to DNA damage.
These observations suggest that specific intron-retention
events may be a signature of responses to various cell
stresses. Interestingly, the mechanisms through which
MYC appears to alter splicing in the context of lympho-
magenesis differ from those in breast cancer. In the
former context, MYC hyperactivation affects the levels of
specific splicing regulators [5], whereas in the latter con-
text, it promotes a global increase in pre-mRNA levels [4]
(although upregulation of a splicing activator has been
reported previously). These ostensibly different findings
suggest that many of the splicing changes associated with
cancer are likely to be context-dependent.
Opportunities for therapeutic intervention
In light of these findings, both Hsu et al. and Koh et al.
explored the therapeutic potential of targeting splicing in
MYC-driven tumors. The idea of targeting the spliceo-
some is not new, and the first spliceosome inhibitory
compounds were initially identified in the late 1990s,
while characterizing anti-tumor drugs. However, recent
improvements in chemistry, as well as a better under-
standing of the modes of action of these molecules, have
created novel therapeutic opportunities (reviewed in [9]).
Hsu et al. demonstrate that genetic knockdown of BUD31
or SF3B1, or pharmacological inhibition of SF3B1, can
delay both primary tumor onset and metastasis formation
following injection of MYC-expressing human breast can-
cer cells lines in mice [4]. Similarly, Koh et al. [5] demon-
strate that PRMT5 haploinsufficiency delays MYC-driven
lymphomagenesis in mice. Thus, both studies suggest that
a therapeutic window for splicing inhibition exists in
MYC-driven cancers.
Two conceptually different approaches to splicing inhib-
ition are currently being tested. The first targets general
components of the splicing machinery and inhibits spli-
cing at a global level, for example using small-molecule
inhibitors to target the SF3B complex or the kinases that
phosphorylate SR proteins [9]. These drugs inhibit very
basic steps in splice site recognition, and potentially have
broad cytotoxic effects. Nevertheless, several studies have
reported that cancer cells are more sensitive to these
drugs than normal cells [9], suggesting that general inhib-
ition of splicing could be a viable anti-tumor strategy. The
second approach is to target a tumor-specific splicing
event directly, for example by using antisense oligonucleo-
tides that bind to a transcript in a sequence-specific man-
ner to redirect splicing (reviewed in [10]). This approach
is expected to have fewer off-target effects and might be
more tumor-specific. Identifying a key splicing event, or
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transformation and tumor maintenance will, however, re-
quire a systematic effort.
Although MYC is the most frequently amplified onco-
gene in human cancers and plays a crucial role in trans-
formation, therapeutic strategies that target MYC-driven
tumors are very limited at present. Thus, targeting either
the spliceosome or specific splicing events could poten-
tially provide novel therapeutic targets in the context of
MYC-driven tumors. A detailed understanding of the cell-
type-specific mechanisms through which splicing contrib-
utes to transformation in cooperation with MYC (but not
with other oncogenes) should facilitate the translation of
the new findings to the clinic.
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